• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » British public wants to crowdfund innovative companies

British public wants to crowdfund innovative companies

February 5, 2013
CenterWatch Staff

The British public wants the opportunity to crowdfund innovative British companies. That is the message from a YouGov survey commissioned by the BioIndustry Association (BIA) which shows that nearly nine out of 10 U.K. adults who expressed a preference agree that the general public should be provided with the opportunity to invest modest sums of money, if they wish to, into funds that will be targeted towards innovative companies.

Additionally, the same number of U.K. adults who expressed a preference agrees that the government should consider new funding policies that support innovative companies in the U.K. where bank lending is not an option.

These results demonstrate that the British public supports the introduction of new investment opportunities like the BIA’s Citizens’ Innovation Funds (CIFs) proposal.

“The British public would like the opportunity to invest in innovative British companies,” said Steve Bates, CEO of BIA. “The BIA believes that Citizens’ Innovation Funds would unlock the patriotic potential of the British public to support innovative businesses. These businesses are the key to jobs and growth for the economy of the future.”

Senior executives from BIA member companies met with ministers, including David Gauke MP, exchequer secretary to the treasury, and shadow ministers during the 13th annual Parliament Day to discuss key topics relevant to the bioscience sector including CIFs. The BIA will also be meeting with Treasury officials during the next few weeks to provide them further details of the proposal.

The CIFs would be a tax-advantaged investment scheme for the general public and the concept is based on the hugely successful French FCPI scheme which has raised more than $8.1 billion since its inception, leveraging more than five times the investment compared to the cost of the scheme.

"We believe that for the life sciences sector CIFs complement existing government actions, such as the Biomedical Catalyst, and will help ensure that equity-backed companies are not left behind,” said Bates. “We are also pleased to have brought together a coalition of supporters for the CIFs proposals from organisations such as the Confederation for British Industry, TIGA and the Association of British Healthcare Industries. This coalition recognizes the value that CIFs could present to small- and medium-sized companies across the spectrum of innovation.”

Upcoming Events

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing